So, IL‐17 and IL‐22 blocking strategies including IL‐17/IL‐17R and IL‐22/IL‐22R neutralizing antibodies48, 49 and antagonists of IL‐17 and IL‐2248, 50 hold potential as therapeutic options in bladder cancer. This evidence concerns the gene IL22RA1 and urinary bladder carcinoma.